Literature DB >> 12220885

Regulating the isotypic and idiotypic profile of an anti-PC antibody response: lessons from peptide mimics.

Shannon L Harris1, Ayse Selma Dagtas, Betty Diamond.   

Abstract

Protection against microbial invasion depends not only on the host's ability to mount an immune response, but on its ability to mount the correct immune response. Whether an antibody response is protective or not depends on both the fine antigenic specificity, that may be associated with particular idiotypes and epitope binding characteristics, and the isotype, determining antibody effector function. Thus, both the variable and the constant region of the antibodies induced by a peptide mimotope must be considered when assessing the success of any immunization. Phosphorylcholine (PC), an epitope present on the cell-wall C-polysaccharide of all pneumococcal serotypes, is capable of eliciting a protective antibody response to pneumococcal infection in mice and provides an attractive model system for understanding the immune response generated by peptide mimics. In this system, both the idiotype and isotype of protective antibodies have been determined and the characteristics of the in vivo response are well described and highly reproducible. We describe here the immune response generated by two peptide mimics of PC. Mice immunized with the peptides developed antibodies binding PC and C-polysaccharide. The idiotypic profile of the response differed depending on the peptide, but never included canonical T15(+) antibodies. The isotype of the response to peptide mimics differed depending on a combination of peptide and adjuvant, and included both IgG2a and IgG2b antibodies which are not typically seen in the response to PC. Thus, peptide mimotopes may elicit anti-polysaccharide responses, but fail to elicit the idiotypes and isotypes observed in the protective response to the microbial antigen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220885     DOI: 10.1016/s0161-5890(02)00116-5

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Receptor editing in peripheral B cell tolerance.

Authors:  Jeffrey S Rice; Jeffrey Newman; Chuansheng Wang; Daniel J Michael; Betty Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

2.  A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.

Authors:  Ulrike K Buchwald; Andrew Lees; Michael Steinitz; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.

Authors:  Shahzada Amir; Karsten Hartvigsen; Ayelet Gonen; Gregor Leibundgut; Xuchu Que; Erika Jensen-Jarolim; Oswald Wagner; Sotirios Tsimikas; Joseph L Witztum; Christoph J Binder
Journal:  J Lipid Res       Date:  2012-04-16       Impact factor: 5.922

5.  Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts.

Authors:  Sun Jung Kim; Michele Caton; Chuansheng Wang; Magi Khalil; Zhi-Jie Zhou; John Hardin; Betty Diamond
Journal:  J Exp Med       Date:  2008-09-22       Impact factor: 14.307

6.  The promise of the anti-idiotype concept.

Authors:  Thomas Kieber-Emmons; Bejatohlah Monzavi-Karbassi; Anastas Pashov; Somdutta Saha; Ramachandran Murali; Heinz Kohler
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

Review 7.  Carbohydrate-mimetic peptides for pan anti-tumor responses.

Authors:  Thomas Kieber-Emmons; Somdutta Saha; Anastas Pashov; Behjatolah Monzavi-Karbassi; Ramachandran Murali
Journal:  Front Immunol       Date:  2014-06-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.